# Loyal

> Loyal is a San Francisco clinical-stage veterinary biotech developing the first FDA-track drugs designed to extend the healthy lifespan of dogs. Its lead candidate, LOY-002, is a beef-flavored daily pill for senior dogs that targets metabolic dysfunction in aging. In 2023 it became the first company to receive an FDA acceptance that a drug can be developed to extend lifespan itself - in any species.

- **Founded:** 2020
- **Headquarters:** San Francisco, California, United States
- **Founders:** Celine Halioua (Founder & CEO)
- **Team size:** ~210 employees
- **Products:** LOY-002, LOY-001, LOY-003
- **Notable:** First company in history to receive FDA acceptance that a drug can be developed to extend lifespan (RXE letter for LOY-001, Nov 2023)., FDA Target Animal Safety acceptance for LOY-002 (Jan 2026) - two of three technical sections now complete., Raised $100M Series C in Feb 2026, total funding past $238M.

## Products & services

- **LOY-002** — A beef-flavored daily pill for dogs 10+ years old weighing at least 14 lbs. Targets metabolic dysfunction associated with aging. Lead candidate; on the FDA conditional-approval track.
- **LOY-001** — A long-acting injection administered by veterinarians, aimed at large dogs 7+ years (40+ lbs). Targets IGF-1, the growth hormone pathway linked to the shorter lifespan of big breeds.
- **LOY-003** — A daily pill for large- and giant-breed dogs (60+ lbs, 5+ years), the take-home counterpart to LOY-001.

## Achievements

- First company in history to receive FDA acceptance that a drug can be developed to extend lifespan (RXE letter for LOY-001, Nov 2023).
- FDA Target Animal Safety acceptance for LOY-002 (Jan 2026) - two of three technical sections now complete.
- Raised $100M Series C in Feb 2026, total funding past $238M.
- Largest companion-dog clinical trial enrollment of its kind (LOY-002 STAY study).

## Latest updates

- **2026-02** — Closed $100M Series C led by age1, with Baillie Gifford joining.
- **2026-01** — FDA accepted the Target Animal Safety technical section for LOY-002.
- **2025-02** — FDA Reasonable Expectation of Effectiveness acceptance for LOY-002 in senior dogs.
- **2024-03** — Closed $45M Series B led by Bain Capital Ventures.

## Links

- Website: https://loyal.com
- LinkedIn: https://www.linkedin.com/company/loyalfordogs
- Twitter/X: https://twitter.com/loyalfordogs
- Instagram: https://www.instagram.com/loyalfordogs/

---

Profile page: https://yespress.io/loyal
Published by YesPress — https://yespress.io
Last updated: 2026-05-28